Kornitzer Capital Management Inc. KS Invests $921,000 in LeMaitre Vascular, Inc. $LMAT

Kornitzer Capital Management Inc. KS bought a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 11,090 shares of the medical instruments supplier’s stock, valued at approximately $921,000.

Other large investors have also recently added to or reduced their stakes in the company. Annex Advisory Services LLC lifted its stake in shares of LeMaitre Vascular by 535.2% during the second quarter. Annex Advisory Services LLC now owns 219,667 shares of the medical instruments supplier’s stock worth $18,243,000 after purchasing an additional 185,085 shares in the last quarter. Millennium Management LLC raised its holdings in shares of LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after buying an additional 115,141 shares during the period. Invesco Ltd. lifted its position in LeMaitre Vascular by 34.5% during the 1st quarter. Invesco Ltd. now owns 235,436 shares of the medical instruments supplier’s stock worth $19,753,000 after acquiring an additional 60,438 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in LeMaitre Vascular by 27.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock worth $22,019,000 after acquiring an additional 55,804 shares during the period. Finally, Nuveen LLC acquired a new stake in LeMaitre Vascular during the 1st quarter valued at $4,631,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Up 0.2%

LMAT stock opened at $89.21 on Monday. The firm’s 50-day moving average is $91.31 and its two-hundred day moving average is $86.79. The company has a market capitalization of $2.02 billion, a price-to-earnings ratio of 43.31, a price-to-earnings-growth ratio of 2.30 and a beta of 0.77. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. During the same quarter last year, the business earned $0.52 earnings per share. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular’s payout ratio is currently 38.83%.

Insider Transactions at LeMaitre Vascular

In related news, Director David B. Roberts sold 10,815 shares of the firm’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the transaction, the director owned 17,976 shares of the company’s stock, valued at $1,660,802.64. This trade represents a 37.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of LeMaitre Vascular stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $94.00, for a total value of $235,000.00. Following the transaction, the director directly owned 2,916 shares in the company, valued at approximately $274,104. The trade was a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 120,815 shares of company stock worth $11,280,206. Corporate insiders own 9.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Barrington Research restated an “outperform” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, October 15th. Cantor Fitzgerald upped their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Saturday. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $97.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.